Audrey Hendricks
Concepts (427)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Variation | 12 | 2026 | 996 | 2.510 |
Why?
| | Genome-Wide Association Study | 14 | 2026 | 1537 | 2.180 |
Why?
| | Software | 4 | 2026 | 676 | 1.990 |
Why?
| | Gene Frequency | 8 | 2026 | 496 | 1.480 |
Why?
| | Models, Genetic | 7 | 2025 | 540 | 1.470 |
Why?
| | Dog Diseases | 5 | 2024 | 140 | 1.350 |
Why?
| | Polymorphism, Single Nucleotide | 13 | 2026 | 2240 | 1.100 |
Why?
| | Computer Simulation | 8 | 2026 | 1014 | 1.090 |
Why?
| | Haplotypes | 4 | 2026 | 506 | 1.070 |
Why?
| | Genetic Association Studies | 3 | 2017 | 379 | 0.960 |
Why?
| | Pedigree | 3 | 2021 | 512 | 0.840 |
Why?
| | Exome | 4 | 2022 | 233 | 0.820 |
Why?
| | Models, Statistical | 3 | 2025 | 669 | 0.740 |
Why?
| | Infant Nutritional Physiological Phenomena | 5 | 2026 | 159 | 0.700 |
Why?
| | Diet | 7 | 2026 | 1273 | 0.700 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 368 | 0.670 |
Why?
| | Open Access Publishing | 1 | 2020 | 6 | 0.660 |
Why?
| | Journal Impact Factor | 1 | 2020 | 29 | 0.650 |
Why?
| | Genetic Predisposition to Disease | 10 | 2026 | 2488 | 0.640 |
Why?
| | Mite Infestations | 1 | 2020 | 8 | 0.620 |
Why?
| | Metagenomics | 1 | 2021 | 154 | 0.610 |
Why?
| | Minichromosome Maintenance Complex Component 6 | 1 | 2019 | 1 | 0.590 |
Why?
| | Huntington Disease | 5 | 2012 | 60 | 0.590 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 35 | 0.580 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2019 | 42 | 0.580 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 539 | 0.580 |
Why?
| | Lymphoma | 1 | 2020 | 251 | 0.540 |
Why?
| | Periodicals as Topic | 1 | 2020 | 214 | 0.530 |
Why?
| | Obesity, Morbid | 2 | 2019 | 287 | 0.490 |
Why?
| | Dogs | 7 | 2024 | 517 | 0.470 |
Why?
| | Inheritance Patterns | 2 | 2021 | 49 | 0.460 |
Why?
| | Colorectal Neoplasms | 2 | 2026 | 874 | 0.460 |
Why?
| | Research Design | 1 | 2022 | 1143 | 0.450 |
Why?
| | Dairy Products | 3 | 2021 | 30 | 0.430 |
Why?
| | Meat | 3 | 2021 | 62 | 0.420 |
Why?
| | Toll-Like Receptors | 2 | 2012 | 193 | 0.400 |
Why?
| | Diet, Mediterranean | 2 | 2024 | 27 | 0.390 |
Why?
| | Pediatric Obesity | 2 | 2020 | 635 | 0.390 |
Why?
| | Humans | 62 | 2026 | 146342 | 0.390 |
Why?
| | Penetrance | 2 | 2009 | 30 | 0.370 |
Why?
| | Genes | 1 | 2012 | 215 | 0.350 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1339 | 0.350 |
Why?
| | United Kingdom | 4 | 2020 | 377 | 0.330 |
Why?
| | Genome, Human | 4 | 2021 | 431 | 0.330 |
Why?
| | Alleles | 7 | 2023 | 907 | 0.330 |
Why?
| | Trinucleotide Repeat Expansion | 3 | 2009 | 45 | 0.330 |
Why?
| | Keratinocytes | 1 | 2012 | 190 | 0.330 |
Why?
| | Cyclosporine | 1 | 2012 | 256 | 0.330 |
Why?
| | Linkage Disequilibrium | 2 | 2026 | 260 | 0.310 |
Why?
| | Heterozygote | 2 | 2019 | 311 | 0.310 |
Why?
| | Obesity | 9 | 2025 | 3131 | 0.300 |
Why?
| | Case-Control Studies | 3 | 2026 | 3647 | 0.290 |
Why?
| | Body Mass Index | 4 | 2025 | 2458 | 0.290 |
Why?
| | Robotic Surgical Procedures | 2 | 2025 | 210 | 0.280 |
Why?
| | Salmon | 2 | 2025 | 20 | 0.270 |
Why?
| | Seafood | 2 | 2025 | 25 | 0.270 |
Why?
| | Infant Formula | 2 | 2018 | 71 | 0.260 |
Why?
| | Animals | 21 | 2025 | 38107 | 0.260 |
Why?
| | Child Development | 2 | 2026 | 481 | 0.260 |
Why?
| | Stem Cells | 1 | 2012 | 613 | 0.260 |
Why?
| | Computational Biology | 1 | 2012 | 678 | 0.260 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 829 | 0.250 |
Why?
| | Linear Models | 2 | 2022 | 857 | 0.250 |
Why?
| | Mendelian Randomization Analysis | 1 | 2026 | 68 | 0.240 |
Why?
| | Dietary Sugars | 1 | 2026 | 21 | 0.240 |
Why?
| | Fast Foods | 1 | 2026 | 24 | 0.240 |
Why?
| | Male | 42 | 2026 | 73396 | 0.240 |
Why?
| | Sodium, Dietary | 1 | 2026 | 43 | 0.240 |
Why?
| | Anastomotic Leak | 1 | 2026 | 46 | 0.230 |
Why?
| | Weaning | 1 | 2026 | 50 | 0.230 |
Why?
| | Female | 42 | 2026 | 79499 | 0.230 |
Why?
| | Energy Intake | 4 | 2026 | 507 | 0.230 |
Why?
| | Infant Food | 1 | 2026 | 69 | 0.230 |
Why?
| | Genotype | 6 | 2023 | 1879 | 0.230 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2025 | 33 | 0.230 |
Why?
| | Thyroid Diseases | 1 | 2026 | 45 | 0.230 |
Why?
| | Fish Products | 1 | 2025 | 7 | 0.220 |
Why?
| | Genetics, Population | 2 | 2025 | 226 | 0.220 |
Why?
| | Adrenalectomy | 1 | 2025 | 68 | 0.220 |
Why?
| | Perinatal Care | 1 | 2025 | 61 | 0.220 |
Why?
| | Otitis Externa | 1 | 2024 | 3 | 0.220 |
Why?
| | Tamoxifen | 1 | 2025 | 193 | 0.210 |
Why?
| | Algorithms | 2 | 2026 | 1849 | 0.210 |
Why?
| | Prevalence | 3 | 2024 | 2861 | 0.210 |
Why?
| | Learning Curve | 1 | 2025 | 71 | 0.210 |
Why?
| | Cardiovascular Diseases | 3 | 2024 | 2219 | 0.210 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2025 | 196 | 0.200 |
Why?
| | Middle Aged | 24 | 2026 | 36619 | 0.200 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2025 | 99 | 0.200 |
Why?
| | Colonic Neoplasms | 1 | 2026 | 259 | 0.200 |
Why?
| | Hypothalamus | 3 | 2019 | 161 | 0.200 |
Why?
| | Energy Metabolism | 3 | 2019 | 930 | 0.190 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 88 | 0.190 |
Why?
| | Dysbiosis | 1 | 2024 | 184 | 0.190 |
Why?
| | Anthropometry | 3 | 2018 | 204 | 0.180 |
Why?
| | Lactation | 1 | 2024 | 193 | 0.180 |
Why?
| | Parkinson Disease | 4 | 2011 | 614 | 0.180 |
Why?
| | Dietary Supplements | 2 | 2024 | 587 | 0.180 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2024 | 178 | 0.180 |
Why?
| | Micronutrients | 2 | 2026 | 102 | 0.180 |
Why?
| | Aged | 18 | 2026 | 26432 | 0.170 |
Why?
| | Thyroid Neoplasms | 1 | 2026 | 380 | 0.170 |
Why?
| | Iodine | 1 | 2021 | 26 | 0.170 |
Why?
| | Zinc | 1 | 2024 | 310 | 0.160 |
Why?
| | Alopecia | 1 | 2020 | 33 | 0.160 |
Why?
| | Hair Follicle | 1 | 2020 | 35 | 0.160 |
Why?
| | Quantitative Trait Loci | 3 | 2019 | 388 | 0.160 |
Why?
| | Pro-Opiomelanocortin | 1 | 2020 | 20 | 0.160 |
Why?
| | Health Benefit Plans, Employee | 3 | 2000 | 25 | 0.160 |
Why?
| | Laparoscopy | 1 | 2025 | 487 | 0.160 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 192 | 0.160 |
Why?
| | Mice | 9 | 2022 | 18297 | 0.160 |
Why?
| | Multifactorial Inheritance | 1 | 2022 | 243 | 0.150 |
Why?
| | Dietary Approaches To Stop Hypertension | 1 | 2020 | 14 | 0.150 |
Why?
| | Sequence Analysis, DNA | 3 | 2017 | 771 | 0.150 |
Why?
| | Muscle Proteins | 2 | 2019 | 242 | 0.150 |
Why?
| | Receptors, Cell Surface | 2 | 2019 | 371 | 0.150 |
Why?
| | Breeding | 1 | 2019 | 64 | 0.150 |
Why?
| | Risk Factors | 5 | 2026 | 10921 | 0.150 |
Why?
| | Nuclear Receptor Coactivator 1 | 1 | 2019 | 5 | 0.150 |
Why?
| | Melanocortins | 1 | 2019 | 1 | 0.150 |
Why?
| | Organic Chemicals | 1 | 2020 | 113 | 0.140 |
Why?
| | Food | 1 | 2020 | 149 | 0.140 |
Why?
| | Poisson Distribution | 1 | 2018 | 77 | 0.140 |
Why?
| | Telomere Shortening | 1 | 2018 | 20 | 0.140 |
Why?
| | Nerve Tissue Proteins | 3 | 2019 | 597 | 0.140 |
Why?
| | Semaphorins | 1 | 2019 | 37 | 0.140 |
Why?
| | Longitudinal Studies | 2 | 2026 | 3017 | 0.140 |
Why?
| | Thinness | 1 | 2019 | 100 | 0.140 |
Why?
| | Metabolomics | 2 | 2021 | 738 | 0.130 |
Why?
| | Adult | 19 | 2025 | 41087 | 0.130 |
Why?
| | Rectum | 1 | 2019 | 180 | 0.130 |
Why?
| | Chromogranins | 1 | 2017 | 13 | 0.130 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2017 | 9 | 0.130 |
Why?
| | Stomach | 1 | 2017 | 106 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2019 | 778 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 457 | 0.130 |
Why?
| | Rodentia | 1 | 2017 | 63 | 0.130 |
Why?
| | Brain | 5 | 2019 | 2991 | 0.120 |
Why?
| | Consumer Behavior | 1 | 1997 | 68 | 0.120 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2017 | 61 | 0.120 |
Why?
| | Esophagectomy | 1 | 2017 | 136 | 0.120 |
Why?
| | Colon | 1 | 2019 | 304 | 0.120 |
Why?
| | Brain Neoplasms | 1 | 2026 | 1325 | 0.120 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2599 | 0.120 |
Why?
| | Population | 1 | 2016 | 30 | 0.120 |
Why?
| | Metabolome | 1 | 2020 | 390 | 0.120 |
Why?
| | Neurons | 4 | 2019 | 1668 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 444 | 0.110 |
Why?
| | Survival Analysis | 1 | 2019 | 1378 | 0.110 |
Why?
| | Trinucleotide Repeats | 2 | 2012 | 31 | 0.110 |
Why?
| | Esophagus | 1 | 2017 | 260 | 0.110 |
Why?
| | Interleukin-8 | 2 | 2017 | 268 | 0.110 |
Why?
| | Health | 1 | 2015 | 81 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 507 | 0.110 |
Why?
| | Prognosis | 2 | 2026 | 4351 | 0.110 |
Why?
| | Telomere | 1 | 2018 | 300 | 0.110 |
Why?
| | Quality Assurance, Health Care | 1 | 1997 | 349 | 0.110 |
Why?
| | Disease | 1 | 2015 | 97 | 0.110 |
Why?
| | Models, Molecular | 2 | 2017 | 1574 | 0.110 |
Why?
| | Iron | 1 | 2017 | 359 | 0.110 |
Why?
| | Odds Ratio | 1 | 2017 | 1077 | 0.100 |
Why?
| | Mutation | 3 | 2017 | 4093 | 0.100 |
Why?
| | Protein Conformation | 1 | 2017 | 916 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1942 | 0.100 |
Why?
| | Dietary Proteins | 3 | 2020 | 135 | 0.100 |
Why?
| | Transcription Factors | 2 | 2019 | 1730 | 0.100 |
Why?
| | Homeodomain Proteins | 1 | 2017 | 525 | 0.100 |
Why?
| | Infant | 6 | 2026 | 10114 | 0.100 |
Why?
| | MicroRNAs | 1 | 2019 | 699 | 0.100 |
Why?
| | Age of Onset | 5 | 2013 | 558 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2418 | 0.090 |
Why?
| | Neostriatum | 1 | 2012 | 37 | 0.090 |
Why?
| | Codon, Terminator | 1 | 2012 | 25 | 0.090 |
Why?
| | Genetic Testing | 2 | 2013 | 492 | 0.090 |
Why?
| | Mutation Rate | 1 | 2012 | 37 | 0.090 |
Why?
| | Veterinary Medicine | 1 | 2012 | 12 | 0.090 |
Why?
| | Biomarkers | 5 | 2024 | 4340 | 0.090 |
Why?
| | Population Density | 1 | 2012 | 91 | 0.090 |
Why?
| | Genetic Linkage | 2 | 2011 | 271 | 0.090 |
Why?
| | Cell Proliferation | 1 | 2019 | 2502 | 0.090 |
Why?
| | Phenotype | 4 | 2026 | 3206 | 0.080 |
Why?
| | Recombination, Genetic | 1 | 2012 | 202 | 0.080 |
Why?
| | Genetic Loci | 1 | 2012 | 273 | 0.080 |
Why?
| | Body Weight | 3 | 2019 | 968 | 0.080 |
Why?
| | Atrial Fibrillation | 1 | 2016 | 560 | 0.080 |
Why?
| | Cohort Studies | 6 | 2021 | 6077 | 0.080 |
Why?
| | Nutritional Status | 2 | 2024 | 346 | 0.080 |
Why?
| | Intestinal Diseases | 1 | 2010 | 43 | 0.080 |
Why?
| | Triglycerides | 2 | 2026 | 527 | 0.080 |
Why?
| | Cells, Cultured | 2 | 2020 | 4118 | 0.070 |
Why?
| | Atherosclerosis | 1 | 2013 | 410 | 0.070 |
Why?
| | Databases, Genetic | 3 | 2017 | 239 | 0.070 |
Why?
| | Gastrointestinal Microbiome | 1 | 2017 | 769 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2026 | 17438 | 0.070 |
Why?
| | Cerebral Cortex | 1 | 2012 | 485 | 0.070 |
Why?
| | Gene Expression | 2 | 2017 | 1463 | 0.070 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1543 | 0.070 |
Why?
| | ELAV Proteins | 1 | 2008 | 14 | 0.070 |
Why?
| | Bacterial Infections | 1 | 2010 | 247 | 0.070 |
Why?
| | Genomic Instability | 1 | 2008 | 64 | 0.070 |
Why?
| | Serine | 1 | 2008 | 142 | 0.070 |
Why?
| | Glucocorticoids | 1 | 2012 | 536 | 0.070 |
Why?
| | Glycine | 1 | 2008 | 184 | 0.060 |
Why?
| | Leptin | 2 | 2019 | 248 | 0.060 |
Why?
| | tau Proteins | 1 | 2008 | 111 | 0.060 |
Why?
| | Pilot Projects | 3 | 2025 | 1888 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1224 | 0.060 |
Why?
| | Alcohol Dehydrogenase | 1 | 2026 | 21 | 0.060 |
Why?
| | Young Adult | 5 | 2024 | 14330 | 0.060 |
Why?
| | DNA Methylation | 2 | 2025 | 725 | 0.060 |
Why?
| | Genetic Pleiotropy | 1 | 2026 | 37 | 0.060 |
Why?
| | Syndrome | 2 | 2017 | 380 | 0.060 |
Why?
| | Nutritive Value | 1 | 2026 | 41 | 0.060 |
Why?
| | Pregnancy | 3 | 2025 | 7230 | 0.060 |
Why?
| | Diet Records | 1 | 2026 | 87 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2026 | 5439 | 0.060 |
Why?
| | DNA Repair | 1 | 2008 | 255 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2012 | 844 | 0.060 |
Why?
| | Zimbabwe | 1 | 2025 | 76 | 0.060 |
Why?
| | Aged, 80 and over | 6 | 2018 | 8391 | 0.060 |
Why?
| | Species Specificity | 2 | 2020 | 543 | 0.060 |
Why?
| | Xanthophylls | 1 | 2025 | 19 | 0.060 |
Why?
| | CpG Islands | 1 | 2025 | 175 | 0.060 |
Why?
| | Isomerism | 1 | 2025 | 55 | 0.050 |
Why?
| | Food Handling | 1 | 2025 | 33 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2013 | 1247 | 0.050 |
Why?
| | Malassezia | 1 | 2024 | 5 | 0.050 |
Why?
| | Massachusetts | 2 | 2013 | 178 | 0.050 |
Why?
| | Homeostasis | 2 | 2019 | 646 | 0.050 |
Why?
| | Crosses, Genetic | 2 | 2019 | 120 | 0.050 |
Why?
| | Fluoroquinolones | 1 | 2024 | 44 | 0.050 |
Why?
| | Leukocytes | 2 | 2018 | 301 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2010 | 666 | 0.050 |
Why?
| | Pharmacogenetics | 1 | 2025 | 176 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2012 | 2791 | 0.050 |
Why?
| | Preconception Care | 1 | 2024 | 50 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4580 | 0.050 |
Why?
| | India | 1 | 2024 | 213 | 0.050 |
Why?
| | Prenatal Care | 1 | 2025 | 310 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 376 | 0.050 |
Why?
| | Biopsy | 2 | 2020 | 1075 | 0.050 |
Why?
| | Child, Preschool | 4 | 2021 | 11913 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2012 | 1408 | 0.050 |
Why?
| | Meta-Analysis as Topic | 2 | 2017 | 173 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 123 | 0.050 |
Why?
| | Age Factors | 3 | 2018 | 3347 | 0.050 |
Why?
| | Weight Gain | 1 | 2026 | 562 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2017 | 2092 | 0.040 |
Why?
| | Cholesterol | 1 | 2023 | 411 | 0.040 |
Why?
| | Cattle | 1 | 2024 | 940 | 0.040 |
Why?
| | Amino Acids, Essential | 1 | 2021 | 13 | 0.040 |
Why?
| | Isoleucine | 1 | 2021 | 15 | 0.040 |
Why?
| | Tanzania | 1 | 2021 | 76 | 0.040 |
Why?
| | Survival Rate | 1 | 2026 | 2092 | 0.040 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2021 | 39 | 0.040 |
Why?
| | United States | 5 | 2026 | 16136 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2024 | 6460 | 0.040 |
Why?
| | Child | 5 | 2021 | 22693 | 0.040 |
Why?
| | Hospitals, Veterans | 2 | 2000 | 256 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 712 | 0.040 |
Why?
| | Phenylalanine | 1 | 2021 | 69 | 0.040 |
Why?
| | Pregnancy Trimester, First | 1 | 2021 | 140 | 0.040 |
Why?
| | Valine | 1 | 2021 | 84 | 0.040 |
Why?
| | Carnitine | 1 | 2021 | 91 | 0.040 |
Why?
| | Leucine | 1 | 2021 | 116 | 0.040 |
Why?
| | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2011 | 11 | 0.040 |
Why?
| | Hair | 1 | 2020 | 81 | 0.040 |
Why?
| | Principal Component Analysis | 2 | 2011 | 192 | 0.040 |
Why?
| | Biotransformation | 1 | 2020 | 61 | 0.040 |
Why?
| | Urinalysis | 1 | 2020 | 82 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2134 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2026 | 850 | 0.040 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2020 | 175 | 0.040 |
Why?
| | Gene Knock-In Techniques | 1 | 2019 | 60 | 0.040 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1107 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2000 | 109 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1358 | 0.040 |
Why?
| | DNA Mutational Analysis | 2 | 2011 | 410 | 0.030 |
Why?
| | Nelfinavir | 1 | 1998 | 7 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2018 | 53 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 6034 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2018 | 32 | 0.030 |
Why?
| | Membrane Potentials | 1 | 2019 | 278 | 0.030 |
Why?
| | Sex Factors | 2 | 2018 | 2107 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2024 | 609 | 0.030 |
Why?
| | Milk | 1 | 2018 | 117 | 0.030 |
Why?
| | Fetal Development | 1 | 2021 | 297 | 0.030 |
Why?
| | HIV Protease Inhibitors | 1 | 1998 | 69 | 0.030 |
Why?
| | Conversion to Open Surgery | 1 | 2017 | 22 | 0.030 |
Why?
| | Proteins | 2 | 2017 | 1022 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2020 | 588 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2012 | 612 | 0.030 |
Why?
| | Proteobacteria | 1 | 2017 | 15 | 0.030 |
Why?
| | Bifidobacterium | 1 | 2017 | 21 | 0.030 |
Why?
| | Thorax | 1 | 2017 | 51 | 0.030 |
Why?
| | Clostridium | 1 | 2017 | 19 | 0.030 |
Why?
| | Neurosecretory Systems | 1 | 2017 | 31 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 426 | 0.030 |
Why?
| | Gene Deletion | 1 | 2019 | 385 | 0.030 |
Why?
| | Insurance, Health, Reimbursement | 1 | 1998 | 97 | 0.030 |
Why?
| | Physical Chromosome Mapping | 1 | 2017 | 21 | 0.030 |
Why?
| | Powders | 1 | 2017 | 45 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2000 | 211 | 0.030 |
Why?
| | Lipodystrophy | 1 | 2017 | 12 | 0.030 |
Why?
| | Genes, Homeobox | 1 | 2017 | 50 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2020 | 615 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2000 | 343 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2019 | 334 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1763 | 0.030 |
Why?
| | Patient Positioning | 1 | 2017 | 73 | 0.030 |
Why?
| | Operative Time | 1 | 2017 | 195 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2017 | 164 | 0.030 |
Why?
| | Neoplasm, Residual | 1 | 2017 | 143 | 0.030 |
Why?
| | Kenya | 1 | 2017 | 129 | 0.030 |
Why?
| | Abdomen | 1 | 2017 | 142 | 0.030 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2016 | 40 | 0.030 |
Why?
| | Aftercare | 1 | 1998 | 225 | 0.030 |
Why?
| | Islands | 1 | 2016 | 3 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 750 | 0.030 |
Why?
| | Croatia | 1 | 2016 | 4 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 157 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2016 | 67 | 0.030 |
Why?
| | Chromosome Mapping | 1 | 2017 | 508 | 0.030 |
Why?
| | Drosophila | 1 | 2017 | 168 | 0.030 |
Why?
| | Eating | 1 | 2019 | 386 | 0.030 |
Why?
| | Body Height | 1 | 2017 | 205 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1500 | 0.030 |
Why?
| | Potassium Channels | 1 | 2016 | 149 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2018 | 320 | 0.030 |
Why?
| | Reproductive Isolation | 1 | 2016 | 44 | 0.030 |
Why?
| | Skin | 1 | 2020 | 701 | 0.030 |
Why?
| | Genetics, Medical | 1 | 2015 | 23 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2015 | 53 | 0.030 |
Why?
| | Choice Behavior | 1 | 1997 | 179 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 2016 | 154 | 0.030 |
Why?
| | Birth Weight | 1 | 2018 | 521 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 110 | 0.030 |
Why?
| | Time Factors | 1 | 2026 | 7109 | 0.030 |
Why?
| | Reference Standards | 1 | 2015 | 176 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 1997 | 287 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2016 | 752 | 0.030 |
Why?
| | Health Services Research | 1 | 1997 | 390 | 0.030 |
Why?
| | Zebrafish | 1 | 2019 | 536 | 0.030 |
Why?
| | Feces | 1 | 2017 | 496 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 1997 | 640 | 0.030 |
Why?
| | Base Sequence | 1 | 2017 | 2123 | 0.030 |
Why?
| | Pseudogenes | 1 | 2013 | 20 | 0.020 |
Why?
| | Hyperphagia | 1 | 2013 | 37 | 0.020 |
Why?
| | Adiponectin | 1 | 2015 | 243 | 0.020 |
Why?
| | Lipoprotein Lipase | 1 | 2013 | 55 | 0.020 |
Why?
| | Fatty Acid Desaturases | 1 | 2013 | 32 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2363 | 0.020 |
Why?
| | Cell Line | 1 | 2019 | 2814 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2013 | 360 | 0.020 |
Why?
| | Blood Pressure | 1 | 2020 | 1765 | 0.020 |
Why?
| | Prospective Studies | 1 | 2025 | 8123 | 0.020 |
Why?
| | Escherichia coli | 1 | 2017 | 832 | 0.020 |
Why?
| | Adolescent | 3 | 2019 | 22557 | 0.020 |
Why?
| | Caudate Nucleus | 1 | 2012 | 23 | 0.020 |
Why?
| | Gliosis | 1 | 2012 | 30 | 0.020 |
Why?
| | Autopsy | 1 | 2012 | 96 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 902 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2017 | 2070 | 0.020 |
Why?
| | Infusions, Parenteral | 1 | 2012 | 47 | 0.020 |
Why?
| | State Health Plans | 1 | 1992 | 28 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2016 | 502 | 0.020 |
Why?
| | England | 1 | 2012 | 106 | 0.020 |
Why?
| | Cat Diseases | 1 | 2012 | 37 | 0.020 |
Why?
| | HIV-1 | 1 | 1998 | 913 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 533 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2013 | 307 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 152 | 0.020 |
Why?
| | Cats | 1 | 2012 | 226 | 0.020 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 231 | 0.020 |
Why?
| | Organ Size | 1 | 2012 | 465 | 0.020 |
Why?
| | Cadaver | 1 | 2012 | 304 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 801 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2013 | 834 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 1998 | 881 | 0.020 |
Why?
| | Medically Uninsured | 1 | 1992 | 134 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2012 | 496 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3545 | 0.020 |
Why?
| | Transcriptome | 1 | 2017 | 1068 | 0.020 |
Why?
| | Anti-HIV Agents | 1 | 1998 | 914 | 0.020 |
Why?
| | Family Health | 1 | 2011 | 194 | 0.020 |
Why?
| | Fatty Acids | 1 | 2013 | 460 | 0.020 |
Why?
| | Genomics | 1 | 2015 | 853 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2013 | 1075 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 1125 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11821 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 872 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2838 | 0.020 |
Why?
| | MutS Homolog 3 Protein | 1 | 2008 | 2 | 0.020 |
Why?
| | Huntingtin Protein | 1 | 2008 | 13 | 0.020 |
Why?
| | MutS Homolog 2 Protein | 1 | 2008 | 12 | 0.020 |
Why?
| | ELAV-Like Protein 4 | 1 | 2008 | 1 | 0.020 |
Why?
| | DNA Repeat Expansion | 1 | 2008 | 10 | 0.020 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2008 | 54 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 1053 | 0.020 |
Why?
| | Lipids | 1 | 2013 | 714 | 0.020 |
Why?
| | Random Allocation | 1 | 2008 | 366 | 0.020 |
Why?
| | Aging | 1 | 2018 | 1996 | 0.020 |
Why?
| | Corpus Striatum | 1 | 2008 | 181 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5899 | 0.020 |
Why?
| | Veterans | 1 | 1998 | 1650 | 0.010 |
Why?
| | Inflammation | 1 | 2017 | 2919 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3416 | 0.010 |
Why?
| | Bacteria | 1 | 2010 | 766 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2008 | 1712 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 1997 | 6073 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1827 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2008 | 740 | 0.010 |
Why?
| | HIV Infections | 1 | 1998 | 3215 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2008 | 1468 | 0.010 |
Why?
| | Benchmarking | 1 | 2000 | 193 | 0.010 |
Why?
| | Drug Evaluation | 1 | 1998 | 78 | 0.010 |
Why?
| | Private Sector | 1 | 1998 | 50 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 1998 | 67 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 280 | 0.010 |
Why?
| | Health Care Surveys | 1 | 1998 | 541 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 693 | 0.010 |
Why?
| | Medicare | 1 | 2000 | 920 | 0.010 |
Why?
| | United States Department of Veterans Affairs | 1 | 1998 | 777 | 0.010 |
Why?
| | New York | 1 | 1992 | 128 | 0.010 |
Why?
| | Patient Discharge | 1 | 1998 | 997 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2000 | 2623 | 0.000 |
Why?
|
|
Hendricks's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|